Subsequently, two pyridoisothiazolone analogue inhibitors, PU139 [targeting PCAF, Gcn5, p300 and CREB (cAMP response element-binding) protein (CBP)] and PU141 (inhibiting CBP and p300) were demonstrated to have activity in vitro against a variety of tumour cell lines [362]. The gene discussed is KAT2B; the disease is neoplasm.